DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
Pompano Beach, Jan. 27, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population.
Aptiv Solutions will prepare DS Healthcare's Investigational New Drug Application (IND), for its proprietary topical hair loss treatment, for submission to the United Stated Food and Drug Administration (FDA). An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis to ensure that DS Healthcare's operations are in line with regulatory requirements for drug approval.
Aptiv Solutions is a leading global CRO with extensive global drug development and trial management expertise. Aptiv Solutions has conducted over 2,600 clinical trials and assisted in over 140 FDA and European Union drug and biologic approvals, as well as over 700 medical device approvals and clearances. DS Healthcare recently announced its intention to submit an IND to the FDA. The move follows the Company's patent application filing with the United States Patent and Trademark Office for its prescription hair loss treatment invention.
"Our intention is to move the development of our prescription-grade hair loss product at a swift pace. Aptiv Solutions has been central to the successful development, clinical trials, and subsequent regulatory approval of numerous market leading products and we are pleased to have their support as our CRO," commented DS Healthcare President and CEO, Daniel Khesin.
About Aptiv Solutions
Aptiv Solutions is a global development services company focused on enhancing clinical trial decision-making, efficiency and productivity for pharmaceutical, biotech and medical device sponsors. It is the only CRO to offer design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk-based monitoring. These services span the entire product development cycle from first in human through regulatory approval to post-marketing. Aptiv Solutions has more than 850 professionals in North America, Eastern and Western Europe, Israel and Japan. Learn more at www.aptivsolutions.com.
About DS Healthcare Group
DS Healthcare Group Inc. leads i the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.